The stock of Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has decreased by -0.93 when compared to last closing price of 92.06.Despite this, the company has seen a gain of 0.81% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-24 that The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is It Worth Investing in Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Right Now?
Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has a price-to-earnings ratio of 104.68x that is above its average ratio. Additionally, the 36-month beta value for BMRN is 0.30. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 7 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for BMRN is 185.93M and currently, short sellers hold a 1.65% ratio of that float. The average trading volume of BMRN on April 25, 2024 was 1.40M shares.
BMRN’s Market Performance
BMRN stock saw an increase of 0.81% in the past week, with a monthly gain of 5.41% and a quarterly increase of -1.20%. The volatility ratio for the week is 1.90%, and the volatility levels for the last 30 days are 1.87% for Biomarin Pharmaceutical Inc. (BMRN). The simple moving average for the past 20 days is 2.39% for BMRN’s stock, with a 2.39% simple moving average for the past 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Wells Fargo repeating the rating for BMRN by listing it as a “Overweight.” The predicted price for BMRN in the upcoming period, according to Wells Fargo is $100 based on the research report published on November 15, 2023 of the previous year 2023.
Bernstein, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $82. The rating they have provided for BMRN stocks is “Mkt Perform” according to the report published on October 23rd, 2023.
BMRN Trading at 3.97% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.40% of loss for the given period.
Volatility was left at 1.87%, however, over the last 30 days, the volatility rate increased by 1.90%, as shares surge +3.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.42% upper at present.
During the last 5 trading sessions, BMRN rose by +0.81%, which changed the moving average for the period of 200-days by +6.64% in comparison to the 20-day moving average, which settled at $89.25. In addition, Biomarin Pharmaceutical Inc. saw -5.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from BIENAIME JEAN JACQUES, who sale 20,000 shares at the price of $91.26 back on Apr 12 ’24. After this action, BIENAIME JEAN JACQUES now owns 474,994 shares of Biomarin Pharmaceutical Inc., valued at $1,825,200 using the latest closing price.
BIENAIME JEAN JACQUES, the Director of Biomarin Pharmaceutical Inc., sale 20,000 shares at $90.99 during a trade that took place back on Apr 11 ’24, which means that BIENAIME JEAN JACQUES is holding 474,994 shares at $1,819,800 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.81 for the gross margin
The net margin for Biomarin Pharmaceutical Inc. stands at 0.14. The total capital return value is set at 0.02. Equity return is now at value 3.51, with 2.54 for asset returns.
Based on Biomarin Pharmaceutical Inc. (BMRN), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 0.04. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -25.06.
Currently, EBITDA for the company is 261.98 million with net debt to EBITDA at 3.85. When we switch over and look at the enterprise to sales, we see a ratio of 0.55. The receivables turnover for the company is 1.02for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.51.
Conclusion
In conclusion, Biomarin Pharmaceutical Inc. (BMRN) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
